Statin therapy, inflammation, and risk for cardiovascular events: The light from JUPITER is illuminating Peter P. Toth Clinical Trials Report 01 August 2009 Pages: 323 - 325
The therapeutic potential of high-density lipoprotein mimetic agents in coronary artery disease Philippe MeyerAnil NigamJean-Claude Tardif OriginalPaper 01 August 2009 Pages: 329 - 333
Darapladib and atherosclerotic plaque: Should lipoprotein-associated phospholipase A2 be a therapeutic target? Peter A. McCullough OriginalPaper 01 August 2009 Pages: 334 - 337
Low-density lipoprotein in the setting of congestive heart failure: Is lower really better? Tamara Horwich OriginalPaper 01 August 2009 Pages: 343 - 349
Lipid-lowering drugs and risk for cancer Terje R. Pedersen OriginalPaper 01 August 2009 Pages: 350 - 357
ApoB versus non-HDL-C: What to do when they disagree Allan SnidermanKen WilliamsChrista Cobbaert OriginalPaper 01 August 2009 Pages: 358 - 363
Thienopyridine therapy and risk for cardiovascular events in secondary prevention Peter P. TothAnnemarie Armani OriginalPaper 01 August 2009 Pages: 364 - 370
Lessons learned from the ONTARGET and TRANSCEND trials Jan Basile OriginalPaper 01 August 2009 Pages: 371 - 376
Lipid lowering and aortic valve disease Anders G. Olsson OriginalPaper 01 August 2009 Pages: 377 - 383
Serum glucose control in diabetic patients with cardiovascular disease: Should we be less aggressive? Sunder Mudaliar OriginalPaper 01 August 2009 Pages: 384 - 390
Increased plasma levels of plant sterols and atherosclerosis: A controversial issue Laura Calpe-BerdielJesús Méndez-GonzálezJoan Carles Escolà-Gil OriginalPaper 01 August 2009 Pages: 391 - 398